$135.2 Million

Xilio Therapeutics, Inc.

Initial Public Offering

Bookrunner, October 2021

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. (“Xilio” or “the Company”) is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built a geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics, with an optimized therapeutic index. Xilio’s molecules are engineered to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. The Company is advancing a number of geographically precise agents through various stages of development. The Company’s most advanced product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody, and XTX202, an interleukin 2 therapy.